Blog

Dec 24, 2024, 16:42

Relapsed head and neck squamous cell carcinoma unrelated to HPV infection

NCI Center for Cancer Research shared on LinkedIn:

“NEW FINDING: Relapsed head and neck squamous cell carcinoma (HNSCC) unrelated to HPV infection carries a poor prognosis; researchers are searching for novel approaches.

A team at CCR led by Claudia M. Palena, Senior Investigator in our Center for Immuno-Oncology, performed a study to evaluate the chemokine receptors CXCR1 and CXCR2 as potential novel targets for the treatment of HPV-negative HNSCC. They showed that inhibiting the two receptors, combined with chemotherapy, may be effective against HIV-negative HNSCC.

Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models – PubMed

Authors: Lucas A Horn, Hanne Lind, Kristen Fousek, Haiyan Qin, Nika Rajabian, Shantel Angstadt, Nicole Hsiao-Sanchez, Miriam M Medina-Enriquez, Marcus D Kelly, Clint T Allen, Sarah M Hammoudeh, Roberto Weigert, Dean Y Maeda, John A Zebala, Claudia Palena

Relapsed head and neck squamous cell carcinoma unrelated to HPV infection

Image: Representative images of tissues from a head and neck cancer tumor tissue array stained for IL-8 mRNA (pink), pan-cytokeratin (CK, green), CXCR1 and CXCR2 mRNA (CXCR1/2, red), or CD45 (white).”

cancer Claudia M. Palena Claudia Palena Clint T Allen Dean Y Maeda Haiyan Qin Hanne Lind head and neck squamous cell carcinoma HPV John A Zebala Kristen Fousek Lucas A Horn Marcus D Kelly Miriam M Medina-Enriquez NCI Center for Cancer Research Nicole Hsiao-Sanchez Nika Rajabian OncoDaily Oncology Roberto Weigert Sarah M Hammoudeh Shantel Angstadt

New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression

Gemma Peters: Heading into 2025 with hope

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Special Coverage